Sentiment-Signal
10,1
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (27.02.2026)
HOCH Abgang Schlüsselpersonen (27.02.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 27.02.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | troductory Note, Item 3.01, Item 3.03, Item 5.01, Item 5.02 and Item 5.03 are incorporated herein by reference. Item 3.0 |
Stammdaten
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
Unternehmen & Branche
| Name | Avidity Biosciences, Inc. |
|---|---|
| Ticker | RNA |
| CIK | 0001599901 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 196,3 Mio. USD |
| Beta | 0,00 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 18,755,000 | -684,631,000 | -4.97 | 1,958,050,000 | 1,688,600,000 |
| 2025-09-30 | 10-Q | 12,475,000 | -174,442,000 | -1.27 | 2,134,209,000 | 1,886,265,000 |
| 2025-06-30 | 10-Q | 3,847,000 | -157,315,000 | -1.21 | 1,368,926,000 | 1,192,664,000 |
| 2025-03-31 | 10-Q | 1,573,000 | -115,773,000 | -0.90 | 1,459,075,000 | 1,328,723,000 |
| 2024-12-31 | 10-K | 10,897,000 | -322,302,000 | -2.89 | 1,563,895,000 | 1,424,959,000 |
| 2024-09-30 | 10-Q | 2,336,000 | -80,398,000 | -0.65 | 1,640,771,000 | 1,503,380,000 |
| 2024-06-30 | 10-Q | 2,045,000 | -70,793,000 | -0.65 | 1,347,425,000 | 1,221,036,000 |
| 2024-03-31 | 10-Q | 3,543,000 | -68,855,000 | -0.79 | 951,474,000 | 830,899,000 |
| 2023-12-31 | 10-K | 9,560,000 | -212,220,000 | -2.91 | 628,555,000 | 500,764,000 |
| 2023-09-30 | 10-Q | 2,818,000 | -52,358,000 | -0.71 | 573,163,000 | 517,468,000 |
| 2023-06-30 | 10-Q | 2,316,000 | -47,025,000 | -0.66 | 610,784,000 | 559,178,000 |
| 2023-03-31 | 10-Q | 2,233,000 | -52,394,000 | -0.74 | 613,976,000 | 558,915,000 |
| 2022-12-31 | 10-K | 9,224,000 | -173,995,000 | -3.34 | 638,800,000 | 578,075,000 |
| 2022-09-30 | 10-Q | 2,482,000 | -43,599,000 | -0.82 | 430,539,000 | 376,982,000 |
| 2022-06-30 | 10-Q | 2,178,000 | -45,690,000 | -0.92 | 420,801,000 | 374,351,000 |
| 2022-03-31 | 10-Q | 1,795,000 | -34,235,000 | -0.71 | 421,135,000 | 375,708,000 |
| 2021-12-31 | 10-K | 9,326,000 | -118,009,000 | -2.85 | 427,580,000 | 381,430,000 |
| 2021-09-30 | 10-Q | 2,163,000 | -29,274,000 | -0.68 | 425,917,000 | 394,877,000 |
| 2021-06-30 | 10-Q | 2,607,000 | -26,353,000 | -0.70 | 290,523,000 | 264,480,000 |
| 2021-03-31 | 10-Q | 2,704,000 | -23,844,000 | 314,752,000 | 286,116,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-01-21 | Hughes Steven George | Officer, Chief Medical Officer | Open Market Sale | -2,017 | 72.45 | -146,131.65 | -23,0% | |
| 2026-01-21 | LEVIN ARTHUR A | Director | Open Market Sale | -1,758 | 72.45 | -127,367.10 | -20,1% | |
| 2026-01-21 | McCarthy Teresa | Officer, Chief Human Resources Officer | Open Market Sale | -1,476 | 72.45 | -106,936.20 | -16,9% | |
| 2026-01-21 | McCarthy Teresa | Officer, Chief Human Resources Officer | Open Market Sale | -1,453 | 72.45 | -105,269.85 | -16,6% | |
| 2026-01-21 | MacLean Michael F | Officer, Chief Financial Officer | Open Market Sale | -2,735 | 72.45 | -198,150.75 | -31,2% | |
| 2026-01-21 | MacLean Michael F | Officer, Chief Financial Officer | Open Market Sale | -1,807 | 72.45 | -130,917.15 | -20,6% | |
| 2026-01-21 | Flanagan W. Michael | Officer, Chief Scientific Officer | Open Market Sale | -3,976 | 72.45 | -288,061.20 | -45,4% | |
| 2026-01-21 | Flanagan W. Michael | Officer, Chief Scientific Officer | Open Market Sale | -2,558 | 72.45 | -185,327.10 | -29,2% | |
| 2026-01-21 | Boyce Sarah | Director, Officer, President and CEO | Open Market Sale | -7,993 | 72.45 | -579,092.85 | -91,3% | |
| 2026-01-21 | Boyce Sarah | Director, Officer, President and CEO | Open Market Sale | -6,394 | 72.45 | -463,245.30 | -73,0% | |
| 2026-01-21 | Hughes Steven George | Officer, Chief Medical Officer | Open Market Sale | -2,878 | 72.45 | -208,511.10 | -32,9% | |
| 2026-01-07 | MacLean Michael F | Officer, Chief Financial Officer | Open Market Sale | -1,974 | 72.23 | -142,582.02 | -22,5% | |
| 2026-01-07 | McCarthy Teresa | Officer, Chief Human Resources Officer | Open Market Sale | -1,965 | 72.23 | -141,931.95 | -22,4% | |
| 2026-01-07 | Moriarty John B | Officer, Chief Legal Officer | Open Market Sale | -2,374 | 72.23 | -171,474.02 | -27,0% | |
| 2026-01-07 | Calderaro Charles III | Officer, Chief Technical Officer | Open Market Sale | -3,727 | 72.23 | -269,201.21 | -42,4% | |
| 2026-01-07 | Flanagan W. Michael | Officer, Chief Scientific Officer | Open Market Sale | -2,373 | 72.23 | -171,401.79 | -27,0% | |
| 2026-01-07 | Boyce Sarah | Director, Officer, President and CEO | Open Market Sale | -8,576 | 72.23 | -619,444.48 | -97,6% | |
| 2026-01-07 | Hughes Steven George | Officer, Chief Medical Officer | Open Market Sale | -2,373 | 72.23 | -171,401.79 | -27,0% | |
| 2025-10-22 | Hughes Steven George | Officer, Chief Medical Officer | Open Market Sale | -2,209 | 47.54 | -105,014.53 | -16,6% | |
| 2025-10-15 | McCarthy Teresa | Officer, Chief Human Resources Officer | Open Market Sale | -20,000 | 50.15 | -1,003,058.00 | -158,1% | |
| 2025-10-03 | Mosbrooker Eric | Officer, Chief Commercial Officer | Open Market Sale | -6,562 | 45.38 | -297,771.09 | -46,9% | |
| 2025-09-22 | Hughes Steven George | Officer, Chief Medical Officer | Open Market Sale | -2,208 | 40.58 | -89,600.64 | -14,1% | |
| 2025-09-15 | McCarthy Teresa | Officer, Chief Human Resources Officer | Open Market Sale | -15,000 | 41.41 | -621,142.50 | -97,9% | |
| 2025-09-15 | Hughes Steven George | Officer, Chief Medical Officer | Open Market Sale | -1,542 | 45.41 | -70,022.22 | -11,0% | |
| 2025-09-11 | Flanagan W. Michael | Officer, Chief Scientific Officer | Open Market Sale | -20,000 | 38.94 | -778,702.00 | -122,7% | |
| 2025-09-05 | WILSON TROY EDWARD | Director | Open Market Sale | -15,000 | 50.00 | -750,000.00 | -118,2% | |
| 2025-09-05 | Boyce Sarah | Director, Officer, President and CEO | Open Market Sale | -50,000 | 49.95 | -2,497,435.00 | -393,6% | |
| 2025-09-05 | WILSON TROY EDWARD | Director | Open Market Sale | -14,500 | 50.00 | -725,000.00 | -114,3% | |
| 2025-09-03 | Mosbrooker Eric | Officer, Chief Commercial Officer | Open Market Sale | -6,563 | 47.07 | -308,935.50 | -48,7% | |
| 2025-09-02 | Gallagher Kathleen P. | Officer, Chief Program Officer | Open Market Sale | -188 | 47.42 | -8,914.96 | -1,4% | |
| 2025-08-28 | Boyce Sarah | Director, Officer, President and CEO | Open Market Sale | -25,000 | 49.39 | -1,234,700.00 | -194,6% | |
| 2025-08-22 | Hughes Steven George | Officer, Chief Medical Officer | Open Market Sale | -2,208 | 46.40 | -102,461.58 | -16,2% | |
| 2025-08-15 | McCarthy Teresa | Officer, Chief Human Resources Officer | Open Market Sale | -10,000 | 46.56 | -465,632.00 | -73,4% | |
| 2025-08-13 | Hughes Steven George | Officer, Chief Medical Officer | Open Market Sale | -1,542 | 46.66 | -71,949.72 | -11,3% | |
| 2025-08-06 | WILSON TROY EDWARD | Director | Open Market Sale | -17,777 | 45.00 | -799,965.00 | -126,1% | |
| 2025-08-06 | WILSON TROY EDWARD | Director | Open Market Sale | -15,000 | 45.00 | -675,000.00 | -106,4% | |
| 2025-08-06 | WILSON TROY EDWARD | Director | Open Market Sale | -7,500 | 45.00 | -337,500.00 | -53,2% | |
| 2025-08-06 | Hughes Steven George | Officer, Chief Medical Officer | Open Market Sale | -33,983 | 42.74 | -1,452,341.67 | -228,9% | |
| 2025-08-06 | Hughes Steven George | Officer, Chief Medical Officer | Open Market Sale | -17,667 | 42.74 | -755,039.88 | -119,0% | |
| 2025-08-06 | Hughes Steven George | Officer, Chief Medical Officer | Open Market Sale | -12,334 | 42.74 | -527,121.86 | -83,1% | |
| 2025-08-06 | Hughes Steven George | Officer, Chief Medical Officer | Open Market Sale | -11,283 | 42.74 | -482,204.96 | -76,0% | |
| 2025-08-06 | Hughes Steven George | Officer, Chief Medical Officer | Open Market Sale | -6,167 | 42.74 | -263,560.93 | -41,5% | |
| 2025-08-06 | MacLean Michael F | Officer, Chief Financial Officer | Open Market Sale | -30,914 | 42.73 | -1,320,843.93 | -208,2% | |
| 2025-08-06 | LEVIN ARTHUR A | Director | Open Market Sale | -107,500 | 47.62 | -5,118,881.25 | -806,8% | |
| 2025-08-06 | Mosbrooker Eric | Officer, Chief Commercial Officer | Open Market Sale | -124,687 | 44.06 | -5,494,033.41 | -866,0% | |
| 2025-08-06 | Mosbrooker Eric | Officer, Chief Commercial Officer | Open Market Sale | -6,120 | 44.06 | -269,663.11 | -42,5% | |
| 2025-08-06 | WILSON TROY EDWARD | Director | Open Market Sale | -22,000 | 45.00 | -990,000.00 | -156,0% | |
| 2025-08-04 | Moriarty John B | Officer, Chief Legal Officer | Open Market Sale | -2,245 | 36.21 | -81,291.45 | -12,8% | |
| 2025-06-17 | Gallagher Kathleen P. | Officer, Chief Program Officer | Open Market Sale | -911 | 30.24 | -27,548.64 | -4,3% | |
| 2025-06-11 | Flanagan W. Michael | Officer, Chief Scientific Officer | Open Market Sale | -20,000 | 32.88 | -657,694.00 | -103,7% | |
| 2025-06-02 | Gallagher Kathleen P. | Officer, Chief Program Officer | Open Market Sale | -5,875 | 32.48 | -190,832.93 | -30,1% | |
| 2025-05-01 | Gallagher Kathleen P. | Officer, Chief Program Officer | Open Market Sale | -5,875 | 32.40 | -190,324.15 | -30,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.